Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Parkinson disease is the second most common neurodegenerative disease. Pain is the frequent non-motor symptom that significantly compromises the quality of life, affecting 80% of patients during the course of the disease. There is currently no evidence-based treatment for PD-related pain in general. Nociceptive pain is the most frequent pain in PD an is frequently musculoskeletal in nature. Epidural spinal cord stimulation is known to provide analgesic effects in several types of pain syndromes. Here we test analgesic effects of a non-invasive trans-spinal magnetic stimulation as an add-on treatment for nociceptive (musculoskeletal) pain directly related to Parkinson disease.
Background: pain is frequent non-motor symptom in Parkinson's disease (PD) that significantly compromises the quality of life, affecting 80% of patients during the course of the disease. Nociceptive pain is the most frequent subtype, mainly musculoskeletal in nature. There is currently no evidence-based treatment for PD-related pain in general. The present study tests the effectiveness and safety of non-invasive trans-spinal magnetic stimulation (TsMS) to treat musculoskeletal pain directly related to PD in a sham-controlled randomized approach.
Patients and Methods: this is a randomized, sham-controlled trial including 40 subjects, aged between 18 and 85 years, with musculoskeletal pain directly related to PD, that will be randomized to receive TsMS active or TsMS sham in a 1:1 ratio. Enrollment will take place at the Pain Center of the University of São Paulo and Movement Disorders Center of the University of São Paulo.
We have decided to perform an interim analysis when 24 patients will be included in the trial in order to assess safety and calculate effect size of the active intervention, after meeting with the research and statistical board. A decision will thereafter be made to, either: 1: halt the study due to futility, 2: continue the study with a new target sample size based on the calculations made with the effect from the n= 24 sample.
Expected results: the study hypothesis is that non-invasive trans-spinal magnetic stimulation is superior to sham and it is safe to use that device in patients with nociceptive (musculoskeletal) pain in PD.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| TsMS active | Active Comparator | Patients undergoing real Trans-spinal Magnetic Stimulation (TsMS) for 8 weeks |
|
| TsMS sham | Sham Comparator | Patients undergoing placebo Trans-spinal Magnetic Stimulation (TsMS) for 8 weeks |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Trans-spinal Magnetic Stimulation (TsMS) | Device | Patients undergoing real TsMS with coil |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Number of responders | Number of individuals presenting 50% pain intensity reduction (on VNS 0-10 average pain of BPI item 5) in the active vs the sham group at the last (8th week) assessment compared to baseline values. | base line (moment of inclusion) and the last day of the patient assessment (2x in two months) |
| Measure | Description | Time Frame |
|---|---|---|
| Change in baseline of Pain | Assessing by score derivated of Parkinson's Disease Pain Classification System (PD-PCS). This score range from 0 (minimum) to 90 (maximum), being considered an effective improvement in the patient's pain when the pain decreases at least in 50% from the basal score. | base line (moment of inclusion) and in the last day after the final session of TMS-e (2x in two months) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Daniel Ciampi, PHD | University of São Paulo | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital das ClÃnicas da Faculdade de Medicina da Universidade de São Paulo | São Paulo | 05403-900 | Brazil |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 36411151 | Derived | Lapa JDDS, da Cunha PHM, Teixeira MJ, Brito Medeiros VM, Fernandes AM, Silva de Morais AD, Graven-Nielsen T, Cury RG, Ciampi de Andrade D. Burst Transspinal Magnetic Stimulation Alleviates Nociceptive Pain in Parkinson Disease-A Pilot Phase II Double-Blind, Randomized Study. Neuromodulation. 2023 Jun;26(4):840-849. doi: 10.1016/j.neurom.2022.10.043. Epub 2022 Nov 18. |
Not provided
Not provided
The complete IPD will be shared with other authors who wish to use it in individual patient data (IPD) meta-analysis. Other specific situations will be discussed on a case-by-case basis.
The IPD will be available after the estimated study completion time (December/2021) and for five years.
use in individual patient data (IPD) meta-analysis. Other specific situations will be discussed on a case-by-case basis.
Not provided
Not provided
| ID | Term |
|---|---|
| D059352 | Musculoskeletal Pain |
| D010300 | Parkinson Disease |
| ID | Term |
|---|---|
| D009135 | Muscular Diseases |
| D009140 | Musculoskeletal Diseases |
| D010146 | Pain |
| D009461 | Neurologic Manifestations |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Sham Trans-spinal Magnetic Stimulation (TsMS) |
| Device |
Patients undergoing placebo TsMS with coil |
|
| Incidence of Treatment-Emergent Adverse Events | The safety of trans-spinal magnetic stimulation (TsMS) will be assessed by measuring the number of participants who experience serious events. Each serious adverse event be described in detail | Immediately after the intervention (session of stimulation) |
| Mood | Assess mood by hospital anxiety and depression scale | base line (moment of inclusion) and the last day of the sessions of TMS-e (2x in two months) |
| Quality of life related to pain relief | Assess by EuroQol- 5 Dimension | base line (moment of inclusion) and the last day of the sessions of TMS-e (2x in two months) |
| Parkinson's disease motor symptoms | Assess by UPDRS part III | base line (moment of inclusion) and the last day of the sessions of TMS-e (2x in two months) |
| Interference in daily activities | measured by brief pain inventory | base line (moment of inclusion) and the last day of the sessions of TMS-e (2x in two months) |
| Global impression of change | Assess % of very much and much improved | base line (moment of inclusion) and the last day of the sessions of TMS-e (2x in two months) |
| D012816 |
| Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D020734 | Parkinsonian Disorders |
| D001480 | Basal Ganglia Diseases |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D009069 | Movement Disorders |
| D000080874 | Synucleinopathies |
| D019636 | Neurodegenerative Diseases |